The global Antiviral Immunoglobulin market size is expected to reach $ 17924 million by 2032, rising at a market growth of 6.4% CAGR during the forecast period (2026-2032).
Antiviral immunoglobulin refers to a class of biological medicinal products containing specific antibodies used for the prevention (prophylaxis) or treatment of viral diseases, operating on the principle of passive immunization. In 2025,global antiviral immunoglobulin production reached approximately 1,731K Kg, with an average global market price of around USD 6,500 per Kg. A factory gross profit of USD 1,950 per Kg with 30% gross margin. A single line full machine capacity production is around 25K Kg per line per year.The upstream segment is highly dependent on the global human plasma supply chain. Downstream demand is concentrated in hospitals,emergency care and research and specialty clinics. A hepatitis B-positive liver transplant recipient receives HBIG therapy following transplantation to reduce the risk of viral recurrence and graft failure. China isleading due to aggressive expansion of plasma-derived biologics manufacturing, increasing healthcare expenditure, and growing domestic demand for immunotherapy products. while US following due to advanced transplant medicine, high immunoglobulin utilization rates, strong reimbursement systems, and continuous expansion of plasma donation infrastructure.
This report studies the global Antiviral Immunoglobulin production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Antiviral Immunoglobulin and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antiviral Immunoglobulin that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Antiviral Immunoglobulin total production and demand, 2021-2032, (kg)
Global Antiviral Immunoglobulin total production value, 2021-2032, (USD Million)
Global Antiviral Immunoglobulin production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (kg), (based on production site)
Global Antiviral Immunoglobulin consumption by region & country, CAGR, 2021-2032 & (kg)
U.S. VS China: Antiviral Immunoglobulin domestic production, consumption, key domestic manufacturers and share
Global Antiviral Immunoglobulin production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (kg)
Global Antiviral Immunoglobulin production by Type, production, value, CAGR, 2021-2032, (USD Million) & (kg)
Global Antiviral Immunoglobulin production by Application, production, value, CAGR, 2021-2032, (USD Million) & (kg)
This report profiles key players in the global Antiviral Immunoglobulin market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), China Biologic Products (CNBG) (China), CSL Behring (US/Germany), Emergent BioSolutions (US), GC Pharma (S. Korea), Grifols (Spain), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Antiviral Immunoglobulin market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (kg) and average price (US$/kg) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Antiviral Immunoglobulin Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Antiviral Immunoglobulin Market, Segmentation by Type:
Human Plasma Derived Polyclonal
Hyperimmune Specific Globulin
Recombinant Monoclonal Antibody (mAb)
Animal Derived (Equine/Ovine)
Others
Global Antiviral Immunoglobulin Market, Segmentation by IgG Purity:
Standard Fractionated Grade (90%–95%)
Clinical High Purity Grade (96%–98%)
Ultra Purified Specialty Grade(99%)
Global Antiviral Immunoglobulin Market, Segmentation by Therapeutic Area:
Transplantation
Infectious Disease Prophylaxis
Immunodeficiency
Neurology (Autoimmune)
Others
Global Antiviral Immunoglobulin Market, Segmentation by Application:
Hospitals
Specialty Clinics
Home Care
Others
Companies Profiled:
ADMA Biologics (US)
AstraZeneca (UK/Sweden)
Bharat Serums & Vaccines (India)
Biotest (Germany)
Boya Bio (China)
China Biologic Products (CNBG) (China)
CSL Behring (US/Germany)
Emergent BioSolutions (US)
GC Pharma (S. Korea)
Grifols (Spain)
Hualan Biological (China)
Intas Pharmaceuticals (India)
Kamada (Israel)
Kedrion (Italy)
LFB Group (France)
Octapharma (Switzerland)
Regeneron (US)
Roche (Switzerland)
Sanofi (France)
Shanghai RAAS (China)
Shuanglin Bio (China)
SK Plasma (S. Korea)
Takeda Pharmaceutical (Japan)
Tiantan Bio (China)
Weiguang Biological (China)
Yuanda Shuyang (China)
Key Questions Answered:
1. How big is the global Antiviral Immunoglobulin market?
2. What is the demand of the global Antiviral Immunoglobulin market?
3. What is the year over year growth of the global Antiviral Immunoglobulin market?
4. What is the production and production value of the global Antiviral Immunoglobulin market?
5. Who are the key producers in the global Antiviral Immunoglobulin market?
6. What are the growth factors driving the market demand?

1 Supply Summary
1.1 Antiviral Immunoglobulin Introduction
1.2 World Antiviral Immunoglobulin Supply & Forecast
1.2.1 World Antiviral Immunoglobulin Production Value (2021 & 2025 & 2032)
1.2.2 World Antiviral Immunoglobulin Production (2021-2032)
1.2.3 World Antiviral Immunoglobulin Pricing Trends (2021-2032)
1.3 World Antiviral Immunoglobulin Production by Region (Based on Production Site)
1.3.1 World Antiviral Immunoglobulin Production Value by Region (2021-2032)
1.3.2 World Antiviral Immunoglobulin Production by Region (2021-2032)
1.3.3 World Antiviral Immunoglobulin Average Price by Region (2021-2032)
1.3.4 North America Antiviral Immunoglobulin Production (2021-2032)
1.3.5 Europe Antiviral Immunoglobulin Production (2021-2032)
1.3.6 China Antiviral Immunoglobulin Production (2021-2032)
1.3.7 Japan Antiviral Immunoglobulin Production (2021-2032)
1.3.8 India Antiviral Immunoglobulin Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Antiviral Immunoglobulin Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Antiviral Immunoglobulin Major Market Trends
2 Demand Summary
2.1 World Antiviral Immunoglobulin Demand (2021-2032)
2.2 World Antiviral Immunoglobulin Consumption by Region
2.2.1 World Antiviral Immunoglobulin Consumption by Region (2021-2026)
2.2.2 World Antiviral Immunoglobulin Consumption Forecast by Region (2027-2032)
2.3 United States Antiviral Immunoglobulin Consumption (2021-2032)
2.4 China Antiviral Immunoglobulin Consumption (2021-2032)
2.5 Europe Antiviral Immunoglobulin Consumption (2021-2032)
2.6 Japan Antiviral Immunoglobulin Consumption (2021-2032)
2.7 South Korea Antiviral Immunoglobulin Consumption (2021-2032)
2.8 ASEAN Antiviral Immunoglobulin Consumption (2021-2032)
2.9 India Antiviral Immunoglobulin Consumption (2021-2032)
3 World Manufacturers Competitive Analysis
3.1 World Antiviral Immunoglobulin Production Value by Manufacturer (2021-2026)
3.2 World Antiviral Immunoglobulin Production by Manufacturer (2021-2026)
3.3 World Antiviral Immunoglobulin Average Price by Manufacturer (2021-2026)
3.4 Antiviral Immunoglobulin Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Antiviral Immunoglobulin Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Antiviral Immunoglobulin in 2025
3.5.3 Global Concentration Ratios (CR8) for Antiviral Immunoglobulin in 2025
3.6 Antiviral Immunoglobulin Market: Overall Company Footprint Analysis
3.6.1 Antiviral Immunoglobulin Market: Region Footprint
3.6.2 Antiviral Immunoglobulin Market: Company Product Type Footprint
3.6.3 Antiviral Immunoglobulin Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 United States VS China VS Rest of the World
4.1 United States VS China: Antiviral Immunoglobulin Production Value Comparison
4.1.1 United States VS China: Antiviral Immunoglobulin Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Antiviral Immunoglobulin Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Antiviral Immunoglobulin Production Comparison
4.2.1 United States VS China: Antiviral Immunoglobulin Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Antiviral Immunoglobulin Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Antiviral Immunoglobulin Consumption Comparison
4.3.1 United States VS China: Antiviral Immunoglobulin Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Antiviral Immunoglobulin Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Antiviral Immunoglobulin Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Antiviral Immunoglobulin Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Antiviral Immunoglobulin Production Value (2021-2026)
4.4.3 United States Based Manufacturers Antiviral Immunoglobulin Production (2021-2026)
4.5 China Based Antiviral Immunoglobulin Manufacturers and Market Share
4.5.1 China Based Antiviral Immunoglobulin Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Antiviral Immunoglobulin Production Value (2021-2026)
4.5.3 China Based Manufacturers Antiviral Immunoglobulin Production (2021-2026)
4.6 Rest of World Based Antiviral Immunoglobulin Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Antiviral Immunoglobulin Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Antiviral Immunoglobulin Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Antiviral Immunoglobulin Production (2021-2026)
5 Market Analysis by Type
5.1 World Antiviral Immunoglobulin Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Human Plasma Derived Polyclonal
5.2.2 Hyperimmune Specific Globulin
5.2.3 Recombinant Monoclonal Antibody (mAb)
5.2.4 Animal Derived (Equine/Ovine)
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Antiviral Immunoglobulin Production by Type (2021-2032)
5.3.2 World Antiviral Immunoglobulin Production Value by Type (2021-2032)
5.3.3 World Antiviral Immunoglobulin Average Price by Type (2021-2032)
6 Market Analysis by IgG Purity
6.1 World Antiviral Immunoglobulin Market Size Overview by IgG Purity: 2021 VS 2025 VS 2032
6.2 Segment Introduction by IgG Purity
6.2.1 Standard Fractionated Grade (90%–95%)
6.2.2 Clinical High Purity Grade (96%–98%)
6.2.3 Ultra Purified Specialty Grade(99%)
6.3 Market Segment by IgG Purity
6.3.1 World Antiviral Immunoglobulin Production by IgG Purity (2021-2032)
6.3.2 World Antiviral Immunoglobulin Production Value by IgG Purity (2021-2032)
6.3.3 World Antiviral Immunoglobulin Average Price by IgG Purity (2021-2032)
7 Market Analysis by Therapeutic Area
7.1 World Antiviral Immunoglobulin Market Size Overview by Therapeutic Area: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Therapeutic Area
7.2.1 Transplantation
7.2.2 Infectious Disease Prophylaxis
7.2.3 Immunodeficiency
7.2.4 Neurology (Autoimmune)
7.2.5 Others
7.3 Market Segment by Therapeutic Area
7.3.1 World Antiviral Immunoglobulin Production by Therapeutic Area (2021-2032)
7.3.2 World Antiviral Immunoglobulin Production Value by Therapeutic Area (2021-2032)
7.3.3 World Antiviral Immunoglobulin Average Price by Therapeutic Area (2021-2032)
8 Market Analysis by Application
8.1 World Antiviral Immunoglobulin Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Specialty Clinics
8.2.3 Home Care
8.2.4 Others
8.3 Market Segment by Application
8.3.1 World Antiviral Immunoglobulin Production by Application (2021-2032)
8.3.2 World Antiviral Immunoglobulin Production Value by Application (2021-2032)
8.3.3 World Antiviral Immunoglobulin Average Price by Application (2021-2032)
9 Company Profiles
9.1 ADMA Biologics (US)
9.1.1 ADMA Biologics (US) Details
9.1.2 ADMA Biologics (US) Major Business
9.1.3 ADMA Biologics (US) Antiviral Immunoglobulin Product and Services
9.1.4 ADMA Biologics (US) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 ADMA Biologics (US) Recent Developments/Updates
9.1.6 ADMA Biologics (US) Competitive Strengths & Weaknesses
9.2 AstraZeneca (UK/Sweden)
9.2.1 AstraZeneca (UK/Sweden) Details
9.2.2 AstraZeneca (UK/Sweden) Major Business
9.2.3 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product and Services
9.2.4 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 AstraZeneca (UK/Sweden) Recent Developments/Updates
9.2.6 AstraZeneca (UK/Sweden) Competitive Strengths & Weaknesses
9.3 Bharat Serums & Vaccines (India)
9.3.1 Bharat Serums & Vaccines (India) Details
9.3.2 Bharat Serums & Vaccines (India) Major Business
9.3.3 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product and Services
9.3.4 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Bharat Serums & Vaccines (India) Recent Developments/Updates
9.3.6 Bharat Serums & Vaccines (India) Competitive Strengths & Weaknesses
9.4 Biotest (Germany)
9.4.1 Biotest (Germany) Details
9.4.2 Biotest (Germany) Major Business
9.4.3 Biotest (Germany) Antiviral Immunoglobulin Product and Services
9.4.4 Biotest (Germany) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Biotest (Germany) Recent Developments/Updates
9.4.6 Biotest (Germany) Competitive Strengths & Weaknesses
9.5 Boya Bio (China)
9.5.1 Boya Bio (China) Details
9.5.2 Boya Bio (China) Major Business
9.5.3 Boya Bio (China) Antiviral Immunoglobulin Product and Services
9.5.4 Boya Bio (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Boya Bio (China) Recent Developments/Updates
9.5.6 Boya Bio (China) Competitive Strengths & Weaknesses
9.6 China Biologic Products (CNBG) (China)
9.6.1 China Biologic Products (CNBG) (China) Details
9.6.2 China Biologic Products (CNBG) (China) Major Business
9.6.3 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product and Services
9.6.4 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 China Biologic Products (CNBG) (China) Recent Developments/Updates
9.6.6 China Biologic Products (CNBG) (China) Competitive Strengths & Weaknesses
9.7 CSL Behring (US/Germany)
9.7.1 CSL Behring (US/Germany) Details
9.7.2 CSL Behring (US/Germany) Major Business
9.7.3 CSL Behring (US/Germany) Antiviral Immunoglobulin Product and Services
9.7.4 CSL Behring (US/Germany) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 CSL Behring (US/Germany) Recent Developments/Updates
9.7.6 CSL Behring (US/Germany) Competitive Strengths & Weaknesses
9.8 Emergent BioSolutions (US)
9.8.1 Emergent BioSolutions (US) Details
9.8.2 Emergent BioSolutions (US) Major Business
9.8.3 Emergent BioSolutions (US) Antiviral Immunoglobulin Product and Services
9.8.4 Emergent BioSolutions (US) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Emergent BioSolutions (US) Recent Developments/Updates
9.8.6 Emergent BioSolutions (US) Competitive Strengths & Weaknesses
9.9 GC Pharma (S. Korea)
9.9.1 GC Pharma (S. Korea) Details
9.9.2 GC Pharma (S. Korea) Major Business
9.9.3 GC Pharma (S. Korea) Antiviral Immunoglobulin Product and Services
9.9.4 GC Pharma (S. Korea) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 GC Pharma (S. Korea) Recent Developments/Updates
9.9.6 GC Pharma (S. Korea) Competitive Strengths & Weaknesses
9.10 Grifols (Spain)
9.10.1 Grifols (Spain) Details
9.10.2 Grifols (Spain) Major Business
9.10.3 Grifols (Spain) Antiviral Immunoglobulin Product and Services
9.10.4 Grifols (Spain) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Grifols (Spain) Recent Developments/Updates
9.10.6 Grifols (Spain) Competitive Strengths & Weaknesses
9.11 Hualan Biological (China)
9.11.1 Hualan Biological (China) Details
9.11.2 Hualan Biological (China) Major Business
9.11.3 Hualan Biological (China) Antiviral Immunoglobulin Product and Services
9.11.4 Hualan Biological (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Hualan Biological (China) Recent Developments/Updates
9.11.6 Hualan Biological (China) Competitive Strengths & Weaknesses
9.12 Intas Pharmaceuticals (India)
9.12.1 Intas Pharmaceuticals (India) Details
9.12.2 Intas Pharmaceuticals (India) Major Business
9.12.3 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product and Services
9.12.4 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Intas Pharmaceuticals (India) Recent Developments/Updates
9.12.6 Intas Pharmaceuticals (India) Competitive Strengths & Weaknesses
9.13 Kamada (Israel)
9.13.1 Kamada (Israel) Details
9.13.2 Kamada (Israel) Major Business
9.13.3 Kamada (Israel) Antiviral Immunoglobulin Product and Services
9.13.4 Kamada (Israel) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Kamada (Israel) Recent Developments/Updates
9.13.6 Kamada (Israel) Competitive Strengths & Weaknesses
9.14 Kedrion (Italy)
9.14.1 Kedrion (Italy) Details
9.14.2 Kedrion (Italy) Major Business
9.14.3 Kedrion (Italy) Antiviral Immunoglobulin Product and Services
9.14.4 Kedrion (Italy) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Kedrion (Italy) Recent Developments/Updates
9.14.6 Kedrion (Italy) Competitive Strengths & Weaknesses
9.15 LFB Group (France)
9.15.1 LFB Group (France) Details
9.15.2 LFB Group (France) Major Business
9.15.3 LFB Group (France) Antiviral Immunoglobulin Product and Services
9.15.4 LFB Group (France) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 LFB Group (France) Recent Developments/Updates
9.15.6 LFB Group (France) Competitive Strengths & Weaknesses
9.16 Octapharma (Switzerland)
9.16.1 Octapharma (Switzerland) Details
9.16.2 Octapharma (Switzerland) Major Business
9.16.3 Octapharma (Switzerland) Antiviral Immunoglobulin Product and Services
9.16.4 Octapharma (Switzerland) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Octapharma (Switzerland) Recent Developments/Updates
9.16.6 Octapharma (Switzerland) Competitive Strengths & Weaknesses
9.17 Regeneron (US)
9.17.1 Regeneron (US) Details
9.17.2 Regeneron (US) Major Business
9.17.3 Regeneron (US) Antiviral Immunoglobulin Product and Services
9.17.4 Regeneron (US) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 Regeneron (US) Recent Developments/Updates
9.17.6 Regeneron (US) Competitive Strengths & Weaknesses
9.18 Roche (Switzerland)
9.18.1 Roche (Switzerland) Details
9.18.2 Roche (Switzerland) Major Business
9.18.3 Roche (Switzerland) Antiviral Immunoglobulin Product and Services
9.18.4 Roche (Switzerland) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Roche (Switzerland) Recent Developments/Updates
9.18.6 Roche (Switzerland) Competitive Strengths & Weaknesses
9.19 Sanofi (France)
9.19.1 Sanofi (France) Details
9.19.2 Sanofi (France) Major Business
9.19.3 Sanofi (France) Antiviral Immunoglobulin Product and Services
9.19.4 Sanofi (France) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.19.5 Sanofi (France) Recent Developments/Updates
9.19.6 Sanofi (France) Competitive Strengths & Weaknesses
9.20 Shanghai RAAS (China)
9.20.1 Shanghai RAAS (China) Details
9.20.2 Shanghai RAAS (China) Major Business
9.20.3 Shanghai RAAS (China) Antiviral Immunoglobulin Product and Services
9.20.4 Shanghai RAAS (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.20.5 Shanghai RAAS (China) Recent Developments/Updates
9.20.6 Shanghai RAAS (China) Competitive Strengths & Weaknesses
9.21 Shuanglin Bio (China)
9.21.1 Shuanglin Bio (China) Details
9.21.2 Shuanglin Bio (China) Major Business
9.21.3 Shuanglin Bio (China) Antiviral Immunoglobulin Product and Services
9.21.4 Shuanglin Bio (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.21.5 Shuanglin Bio (China) Recent Developments/Updates
9.21.6 Shuanglin Bio (China) Competitive Strengths & Weaknesses
9.22 SK Plasma (S. Korea)
9.22.1 SK Plasma (S. Korea) Details
9.22.2 SK Plasma (S. Korea) Major Business
9.22.3 SK Plasma (S. Korea) Antiviral Immunoglobulin Product and Services
9.22.4 SK Plasma (S. Korea) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.22.5 SK Plasma (S. Korea) Recent Developments/Updates
9.22.6 SK Plasma (S. Korea) Competitive Strengths & Weaknesses
9.23 Takeda Pharmaceutical (Japan)
9.23.1 Takeda Pharmaceutical (Japan) Details
9.23.2 Takeda Pharmaceutical (Japan) Major Business
9.23.3 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product and Services
9.23.4 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.23.5 Takeda Pharmaceutical (Japan) Recent Developments/Updates
9.23.6 Takeda Pharmaceutical (Japan) Competitive Strengths & Weaknesses
9.24 Tiantan Bio (China)
9.24.1 Tiantan Bio (China) Details
9.24.2 Tiantan Bio (China) Major Business
9.24.3 Tiantan Bio (China) Antiviral Immunoglobulin Product and Services
9.24.4 Tiantan Bio (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.24.5 Tiantan Bio (China) Recent Developments/Updates
9.24.6 Tiantan Bio (China) Competitive Strengths & Weaknesses
9.25 Weiguang Biological (China)
9.25.1 Weiguang Biological (China) Details
9.25.2 Weiguang Biological (China) Major Business
9.25.3 Weiguang Biological (China) Antiviral Immunoglobulin Product and Services
9.25.4 Weiguang Biological (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.25.5 Weiguang Biological (China) Recent Developments/Updates
9.25.6 Weiguang Biological (China) Competitive Strengths & Weaknesses
9.26 Yuanda Shuyang (China)
9.26.1 Yuanda Shuyang (China) Details
9.26.2 Yuanda Shuyang (China) Major Business
9.26.3 Yuanda Shuyang (China) Antiviral Immunoglobulin Product and Services
9.26.4 Yuanda Shuyang (China) Antiviral Immunoglobulin Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.26.5 Yuanda Shuyang (China) Recent Developments/Updates
9.26.6 Yuanda Shuyang (China) Competitive Strengths & Weaknesses
10 Industry Chain Analysis
10.1 Antiviral Immunoglobulin Industry Chain
10.2 Antiviral Immunoglobulin Upstream Analysis
10.2.1 Antiviral Immunoglobulin Core Raw Materials
10.2.2 Main Manufacturers of Antiviral Immunoglobulin Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Antiviral Immunoglobulin Production Mode
10.6 Antiviral Immunoglobulin Procurement Model
10.7 Antiviral Immunoglobulin Industry Sales Model and Sales Channels
10.7.1 Antiviral Immunoglobulin Sales Model
10.7.2 Antiviral Immunoglobulin Typical Distributors
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer